Overcoming Translational Barriers in Acute Kidney Injury

AKI is a complex clinical condition associated with high mortality, morbidity, and health care costs. Despite improvements in methodology and design of clinical trials, and advances in understanding the underlying pathophysiology of rodent AKI, no pharmacologic agent exists for the prevention or treatment of AKI in humans. To address the barriers that affect successful clinical translation of drug targets identified and validated in preclinical animal models of AKI in this patient population, the National Institute of Diabetes and Digestive and Kidney Diseases convened the“AKIOutcomes:OvercomingBarriers inAKI”workshoponFebruary10–12,2015.Theworkshopuseda reverse translational medicine approach to identify steps necessary to achieve clinical success. During the workshop, breakoutgroupswerechargedfirsttodesignfeasible,phase2,proof-of-conceptclinical trials fordelayedtransplantgraft function, prevention of AKI (primary prevention), and treatment of AKI (secondary prevention and recovery). Breakout groups then were responsible for identification of preclinical animal models that would replicate the pathophysiology of the phase 2 proof-of-concept patient population, including primary and secondary end points. Breakout groups identified considerable gaps in knowledge regarding human AKI, our understanding of the pathophysiology of AKI in preclinical animal models, and the fidelity of cellular and molecular targets that have been evaluated preclinically to provide information regarding human AKI of various etiologies. The workshop concluded with attendees defining a new path forward to a better understanding of the etiology, pathology, and pathophysiology of human AKI. Clin J Am Soc Nephrol 13: 1113–1123, 2018. doi: https://doi.org/10.2215/CJN.06820617 Introduction The lack of effective therapeutic interventions for prevention or treatment of AKI remains a major unmet medical need. AKI has a high mortality rate, and longterm outcomes in those who survive include development of CKD and ESRD. In individuals with preexisting CKD, AKI may accelerate progression to ESRD (1). Thus AKI, once thought to have a benign course in patients who recover, can lead to long-term morbidity, mortality, poor quality of life, and burgeoning health care costs (1). In February of 2015, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) convened the “AKI Outcomes: Overcoming Barriers in AKI” workshop at the National Institutes of Health (NIH). The workshop aimed to integrate and advance collective efforts of the AKI community (2–5) by developing an overarching research strategy to facilitate development and testing of therapies that may meaningfully improve clinical outcomes of AKI. This multidisciplinary meeting brought together clinicians, basic scientists, clinical trialists, and representatives from the US Food and Drug Administration (FDA) and industry. Presenters reviewed current AKI research and participants recommended needed changes regarding pathophysiologic targets, animal models, and clinical trial designs for AKI (6). Importantly, a reverse translational medicine approach laid the foundation for the meeting. In contrast to the linear sequence of preclinical activities historically performed for drug discovery and specifically for AKI (i.e., identifying biologic targets, evaluating target modulators in animal models, and if successful, evaluating a drug in human phase 1 safety and phase 2 proof-of-concept clinical studies), workshop participants proceeded backward, first defining needed clinical trial designs by considering the specific patient population, and then the resulting primary and secondary end points. Subsequently, participants identified the animal model to replicate this patient population. By working backward, participants uncovered considerable gaps in our understanding of human AKI, and of the relevance of AKI animal models and common biologic targets, thereby paving the way for improvements in clinical translation (Figure 1). The workshop included speakers from clinical areas unrelated to AKI, where researchers had successfully addressed challenges similar to those faced by the AKI research community. Breakout sessions followed, including (1) Delayed Transplant Graft Function, (2) Primary AKI Prevention, (3) Secondary AKI Prevention, and (4) Hastening Recovery. Breakout group topics were selected Due to the number of contributing authors, the affiliations are listed at the end of

[1]  Winnie Martinez,et al.  National Institute of Diabetes and Digestive and Kidney Diseases , 2020, Definitions.

[2]  Jenna M. Norton,et al.  Complementary Initiatives from the NIDDK to Advance Kidney Health. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[3]  Somnath Bandyopadhyay,et al.  A Systemic Lupus Erythematosus Endophenotype Characterized by Increased CD8 Cytotoxic Signature Associates with Renal Involvement , 2017, ImmunoHorizons.

[4]  Leah J. Siskind,et al.  Developing better mouse models to study cisplatin-induced kidney injury. , 2017, American journal of physiology. Renal physiology.

[5]  N. Tatonetti,et al.  Unique Transcriptional Programs Identify Subtypes of AKI. , 2017, Journal of the American Society of Nephrology : JASN.

[6]  M. D. de Caestecker,et al.  Bridging translation for acute kidney injury with better preclinical modeling of human disease. , 2016, American journal of physiology. Renal physiology.

[7]  J. Kellum,et al.  Targeting Endogenous Repair Pathways after AKI. , 2016, Journal of the American Society of Nephrology : JASN.

[8]  J. Kellum,et al.  Progression after AKI: Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments. , 2016, Journal of the American Society of Nephrology : JASN.

[9]  K. Nath Models of Human AKI: Resemblance, Reproducibility, and Return on Investment. , 2015, Journal of the American Society of Nephrology : JASN.

[10]  F. Harrell,et al.  Bridging Translation by Improving Preclinical Study Design in AKI. , 2015, Journal of the American Society of Nephrology : JASN.

[11]  Wei Zhang,et al.  Aging increases the susceptibility of cisplatin-induced nephrotoxicity , 2015, AGE.

[12]  P. Hayes,et al.  Contrast Medium-Induced Acute Kidney Injury , 2015, Cardiorenal Medicine.

[13]  S. Wenzel,et al.  Emerging molecular phenotypes of asthma. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[14]  M. Fink,et al.  Strategies to improve drug development for sepsis , 2014, Nature Reviews Drug Discovery.

[15]  Kevin Delucchi,et al.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[16]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[17]  J. Marshall Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.

[18]  S. Perrin Preclinical research: Make mouse studies work , 2014, Nature.

[19]  Sarah C. Emerson,et al.  Imperfect gold standards for biomarker evaluation , 2013, Clinical trials.

[20]  D. Parekh,et al.  Tolerance of the human kidney to isolated controlled ischemia. , 2013, Journal of the American Society of Nephrology : JASN.

[21]  B. Jaber,et al.  Ongoing clinical trials in AKI. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[22]  D. Brennan,et al.  Delayed Graft Function in the Kidney Transplant , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  R. Traystman,et al.  Normothermic cardiac arrest and cardiopulmonary resuscitation: a mouse model of ischemia-reperfusion injury. , 2011, Journal of visualized experiments : JoVE.

[24]  G. Bernard,et al.  ARDS Network (NHLBI) studies: successes and challenges in ARDS clinical research. , 2011, Critical care clinics.

[25]  A. Sharif,et al.  Assessing and Comparing Rival Definitions of Delayed Renal Allograft Function for Predicting Subsequent Graft Failure , 2010, Transplantation.

[26]  K. Nugent,et al.  Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.

[27]  K. Harjai,et al.  Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. , 2004, The American journal of cardiology.

[28]  J. Kellum,et al.  Renal Hemodynamics in AKI: In Search of New Treatment Targets. , 2016, Journal of the American Society of Nephrology : JASN.

[29]  The IPFnet Strategy: Creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[30]  R. Bellomo,et al.  Cardiopulmonary bypass, hemolysis, free iron, acute kidney injury and the impact of bicarbonate. , 2010, Contributions to nephrology.

[31]  W. Lieberthal,et al.  Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable. , 2000, American journal of physiology. Renal physiology.

[32]  W. Raub From the National Institutes of Health. , 1990, JAMA.